204 related articles for article (PubMed ID: 32764384)
1. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.
Mukherjee N; Amato CM; Skees J; Todd KJ; Lambert KA; Robinson WA; Van Gulick R; Weight RM; Dart CR; Tobin RP; McCarter MD; Fujita M; Norris DA; Shellman YG
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764384
[TBL] [Abstract][Full Text] [Related]
2. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Mukherjee N; Skees J; Todd KJ; West DA; Lambert KA; Robinson WA; Amato CM; Couts KL; Van Gulick R; MacBeth M; Nassar K; Tan AC; Zhai Z; Fujita M; Bagby SM; Dart CR; Lambert JR; Norris DA; Shellman YG
Cell Death Dis; 2020 Jun; 11(6):443. PubMed ID: 32513939
[TBL] [Abstract][Full Text] [Related]
3. A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine.
Dart CR; Mukherjee N; Amato CM; Goulding A; MacBeth M; Van Gulick R; Couts KL; Lambert JR; Norris DA; Robinson WA; Shellman YG
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451846
[TBL] [Abstract][Full Text] [Related]
4. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Mandhair H; Bacher U; Pabst T
Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
[TBL] [Abstract][Full Text] [Related]
6. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
Klanova M; Kazantsev D; Pokorna E; Zikmund T; Karolova J; Behounek M; Renesova N; Sovilj D; Kelemen CD; Helman K; Jaksa R; Havranek O; Andera L; Trneny M; Klener P
Mol Cancer Ther; 2022 Jan; 21(1):89-99. PubMed ID: 34728569
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract][Full Text] [Related]
8. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Kohler S; Bacher U; Pabst T
Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
[TBL] [Abstract][Full Text] [Related]
9. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.
Mukherjee N; Katsnelson E; Brunetti TM; Michel K; Couts KL; Lambert KA; Robinson WA; McCarter MD; Norris DA; Tobin RP; Shellman YG
Cell Death Dis; 2024 Mar; 15(3):198. PubMed ID: 38459020
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis Pathway-Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma.
Ledesma DA; Marques-Piubelli ML; Li-Ning-Tapia E; Hudgens C; Gu J; Lazcano R; Casavilca-Zambrano S; Castillo M; Davies MA; Hwu WJ; Aung PP; Giubellino A; Curry JL; Torres-Cabala C
Am J Dermatopathol; 2024 May; ():. PubMed ID: 38718197
[TBL] [Abstract][Full Text] [Related]
11. BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic.
Lin VS; Xu ZF; Huang DCS; Thijssen R
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198338
[TBL] [Abstract][Full Text] [Related]
12. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.
Rys RN; Wever CM; Geoffrion D; Goncalves C; Ghassemian A; Brailovski E; Ryan J; Stoica L; Hébert J; Petrogiannis-Haliotis T; Dmitrienko S; Frenkiel S; Staiger A; Ott G; Steidl C; Scott DW; Sesques P; Del Rincon S; Mann KK; Letai A; Johnson NA
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670870
[TBL] [Abstract][Full Text] [Related]
14. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
[TBL] [Abstract][Full Text] [Related]
15. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
Sale MJ; Cook SJ
Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
[TBL] [Abstract][Full Text] [Related]
16. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
17. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
18. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics.
Mukherjee N; Dart CR; Amato CM; Honig-Frand A; Lambert JR; Lambert KA; Robinson WA; Tobin RP; McCarter MD; Couts KL; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2022 Jul; 142(7):1912-1922.e7. PubMed ID: 34942200
[TBL] [Abstract][Full Text] [Related]
19. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
[TBL] [Abstract][Full Text] [Related]
20. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
